- Home
- Publications
- Publication Search
- Publication Details
Title
Sintilimab for the treatment of non-small cell lung cancer
Authors
Keywords
-
Journal
Biomarker Research
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-18
DOI
10.1186/s40364-022-00363-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-small-cell Lung Cancer
- (2022) Peng Zhang et al. ANNALS OF THORACIC SURGERY
- Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study
- (2022) Xinqing Lin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
- (2022) Shuhang Wang et al. npj Precision Oncology
- The binding epitope of sintilimab on PD-1 revealed by AbMap
- (2021) Mingliang Ma et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios
- (2021) Neal Andruska et al. Journal of Thoracic Oncology
- Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
- (2021) Tianqing Chu et al. Journal of Thoracic Oncology
- Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
- (2021) Ziran Zhao et al. Targeted Oncology
- The efficacy of PD-1 antibody sintilimab on ground glass opacity lesions in patients with early-stage multiple primary lung cancer (CCTC-1901, NCT04026841).
- (2021) Bo Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.
- (2021) Shugeng Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
- (2021) Yunpeng Yang et al. Journal of Thoracic Oncology
- Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
- (2021) Caicun Zhou et al. Journal of Thoracic Oncology
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
- (2021) Xiaoxiang Zhou et al. LANCET ONCOLOGY
- Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial
- (2021) Jianjiao Ni et al. Radiation Oncology
- Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
- (2021) Beatriz Honrubia-Peris et al. Cancers
- Mobile 3-dimensional (3D) C-arm system-assisted transbronchial biopsy and ablation for ground-glass opacity pulmonary nodules: a case report
- (2021) Junxiang Chen et al. Translational Lung Cancer Research
- A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future
- (2021) Sijia Ren et al. Translational Lung Cancer Research
- Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy
- (2021) Mohammad-Javad Sanaei et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
- (2021) E.B. Ulas et al. ESMO Open
- The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
- (2020) Xiuli Tao et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Immune checkpoint signaling and cancer immunotherapy
- (2020) Xing He et al. CELL RESEARCH
- Effect of low-dose radiotherapy on abscopal responses to hypofractionated radiotherapy and anti-PD1 in mice and NSCLC patients
- (2020) Limei Yin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer
- (2020) Lin Zhang et al. MEDICINE
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)
- (2020) Yunpeng Yang et al. Journal of Thoracic Oncology
- Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
- (2020) Haiping Jiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
- (2020) Mairéad G. McNamara et al. CANCER TREATMENT REVIEWS
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
- (2020) Barzin Y. Nabet et al. CELL
- Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer
- (2020) Vincent K. Lam et al. Journal of Thoracic Oncology
- Sintilimab: A Promising Anti-Tumor PD-1 Antibody
- (2020) Lin Zhang et al. Frontiers in Oncology
- Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes
- (2020) Yun Ling et al. npj Precision Oncology
- Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
- (2019) Yuankai Shi et al. Lancet Haematology
- Sintilimab: First Global Approval
- (2019) Sheridan M. Hoy DRUGS
- Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out
- (2019) C. Proto et al. CANCER TREATMENT REVIEWS
- PD‐(L)1 inhibitors vs . chemotherapy vs . their combination in front‐line treatment for NSCLC: An indirect comparison
- (2019) Hengrui Liang et al. INTERNATIONAL JOURNAL OF CANCER
- Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
- (2019) Monireh Mohsenzadegan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
- (2019) Jie Wang et al. mAbs
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- (2019) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
- (2018) Baohui Han et al. BRITISH JOURNAL OF CANCER
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
- (2018) Jian-Ming Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
- (2018) Cheng Xu et al. BMJ-British Medical Journal
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)
- (2016) Yuankai Shi et al. Asia-Pacific Journal of Clinical Oncology
- Clinicopathologic Features of Advanced Squamous NSCLC
- (2016) Mark A. Socinski et al. Journal of Thoracic Oncology
- Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
- (2016) Michael B. Bernstein et al. Nature Reviews Clinical Oncology
- Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
- (2016) Jin Sheng et al. Scientific Reports
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
- (2014) LANCET
- Treatment of Stage I and II Non-small Cell Lung Cancer
- (2013) John A. Howington et al. CHEST
- Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study
- (2012) Runmei Li et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started